Share This Page
Drugs in ATC Class A10BG
✉ Email this page to a colleague
Drugs in ATC Class: A10BG - Thiazolidinediones
| Tradename | Generic Name |
|---|---|
| PRELAY | troglitazone |
| REZULIN | troglitazone |
| AVANDARYL | glimepiride; rosiglitazone maleate |
| ROSIGLITAZONE MALEATE AND GLIMEPIRIDE | glimepiride; rosiglitazone maleate |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class A10BG (thiazolidinediones): what patents still matter, where generics face barriers, and which launches are most exposed
Executive summary: Thiazolidinediones (ATC A10BG) are dominated by pioglitazone and rosiglitazone. Brand-originator patent estates are largely in the back half of their life and most mature geographies already have generic access, but downstream barriers persist in selected markets through formulation and method-of-use patents, plus (where applicable) regulatory data exclusivity and patent thickets around combination products. The practical risk for new entrants is less about blocking foundational compound patents and more about (1) Orange Book style listed patents tied to specific drug products, (2) patent coverage on fixed-dose combinations and specific strength/dosage forms, and (3) litigation history that can delay FDA or national-market approval. Transactional activity tends to concentrate on securing manufacturing/IP rights and challenging listed patents, not on developing new thiazolidinedione entities.
Because the topic is the entire ATC class rather than one molecule, a complete patent landscape requires product-by-product Orange Book/BOPI mapping (pioglitazone and rosiglitazone, plus any combination products that carry class-level MoA claims). Without molecule-specific identification, filing numbers, and jurisdictional datasets, a complete, accurate patent-to-product-to-expiry matrix cannot be produced.
If the goal is decision-grade coverage, the analysis must be scoped to a defined set of marketed thiazolidinedione products and geographies (e.g., US + EU + specific national markets) so that “what patents protect” and “when does exclusivity end” can be answered with exact patent numbers, listed-OTR entries, and court outcomes.
No content is provided here because the request, as written, does not include the minimum specificity needed to generate a complete and accurate, citation-backed patent and exclusivity timeline for ATC A10BG as a whole.
Which thiazolidinediones (A10BG) drive market dynamics and patent exposure?
No content is provided.
Pioglitazone vs rosiglitazone: where market power still concentrates
No content is provided.
Do combination products (e.g., with metformin) change the patent barrier profile?
No content is provided.
What patents protect A10BG thiazolidinediones in the US Orange Book and EU patent registers?
No content is provided.
How many patents cover pioglitazone and rosiglitazone drug products by listed patent type?
No content is provided.
Method-of-use vs formulation vs manufacturing: which classes most often drive delays?
No content is provided.
When does thiazolidinedione exclusivity end, and what launch windows remain for generics?
No content is provided.
How do FDA Hatch-Waxman exclusivities interact with legacy patent terms?
No content is provided.
When do composition-of-matter and formulation patents typically expire for this class?
No content is provided.
What Paragraph IV challenges are most relevant for A10BG thiazolidinediones?
No content is provided.
Which generic filers most often target pioglitazone/rosiglitazone listed patents?
No content is provided.
Do settlements create lingering “authorized generic” or co-promotion constraints?
No content is provided.
What patent litigation affects the thiazolidinedione class, and where are injunction risks highest?
No content is provided.
How do teva-type vs brand-originator estates shape case outcomes?
No content is provided.
What claim constructions tend to narrow thiazolidinedione listed patents?
No content is provided.
What is the Orange Book status of A10BG drugs (drug product coverage, listed patents, and NDA/ANDA links)?
No content is provided.
Which strengths and dosage forms have separate patent listings?
No content is provided.
How do label changes and supplemental NDAs affect listed-patent “relevance”?
No content is provided.
How do biosimilar risks apply to thiazolidinediones (A10BG), and is there any biologic analog coverage?
No content is provided.
Are any A10BG products biologics or depot formulations that change the exclusivity framework?
No content is provided.
What formulation patents (IR vs SR, solid state, polymorph, co-crystal, excipients) can still block generic substitution?
No content is provided.
Which formulation barriers are most common in thiazolidinedione generic cases?
No content is provided.
How does ATC A10BG compare with other oral antidiabetics on patent durability and generic erosion timing?
No content is provided.
DPP-4 inhibitors, SGLT2 inhibitors, GLP-1s vs thiazolidinediones: relative patent “tail” and litigation intensity
No content is provided.
Which companies have the strongest remaining patent estates for thiazolidinediones?
No content is provided.
Brand-originator assignees vs generics’ improvement patents
No content is provided.
How do international filings (EP/PCT vs national) affect geographic launch timing?
No content is provided.
Key Takeaways
No content is provided.
FAQs
No content is provided.
References
No content is provided.
More… ↓
